163 related articles for article (PubMed ID: 22340411)
1. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer.
Zhang YF; Guan YB; Yang B; Wu HY; Dai YT; Zhang SJ; Wang JP; Anoopkumar-Dukie S; Davey AK; Sun ZY
Chin Med J (Engl); 2011 Dec; 124(24):4345-9. PubMed ID: 22340411
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of shed Her2/neu protein in men with prostate cancer correlate with disease progression.
Osman I; Mikhail M; Shuch B; Clute M; Cheli CD; Ghani F; Thiel RP; Taneja SS
J Urol; 2005 Dec; 174(6):2174-7. PubMed ID: 16280758
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer.
Osman I; Scher HI; Drobnjak M; Verbel D; Morris M; Agus D; Ross JS; Cordon-Cardo C
Clin Cancer Res; 2001 Sep; 7(9):2643-7. PubMed ID: 11555574
[TBL] [Abstract][Full Text] [Related]
4. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between HER-2/neu over-expression and androgen independent prostate cancer].
Bai Q; Chen F; Qi J; Chen JH; Wang YX
Zhonghua Nan Ke Xue; 2007 May; 13(5):414-6. PubMed ID: 17569256
[TBL] [Abstract][Full Text] [Related]
7. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
8. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
[TBL] [Abstract][Full Text] [Related]
10. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer.
Di Lorenzo G; Tortora G; D'Armiento FP; De Rosa G; Staibano S; Autorino R; D'Armiento M; De Laurentiis M; De Placido S; Catalano G; Bianco AR; Ciardiello F
Clin Cancer Res; 2002 Nov; 8(11):3438-44. PubMed ID: 12429632
[TBL] [Abstract][Full Text] [Related]
11. Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ.
Hou H; Chen W; Zhao L; Zuo Q; Zhang G; Zhang X; Wang H; Gong H; Li X; Wang M; Wang Y; Li X
J Clin Pathol; 2012 Dec; 65(12):1088-96. PubMed ID: 22944623
[TBL] [Abstract][Full Text] [Related]
12. Increased expression of elongation factor-1α is significantly correlated with poor prognosis of human prostate cancer.
Liu H; Ding J; Chen F; Fan B; Gao N; Yang Z; Qi L
Scand J Urol Nephrol; 2010 Nov; 44(5):277-83. PubMed ID: 20545466
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of DNA ploidy, bcl-2 and p53 in localized prostate adenocarcinoma incidentally discovered at transurethral prostatectomy.
Abaza R; Diaz LK; Laskin WB; Pins MR
J Urol; 2006 Dec; 176(6 Pt 1):2701-5. PubMed ID: 17085199
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.
Isharwal S; Miller MC; Epstein JI; Mangold LA; Humphreys E; Partin AW; Veltri RW
Int J Cancer; 2008 Dec; 123(11):2636-43. PubMed ID: 18767043
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in prostate cancer.
Stattin P
Scand J Urol Nephrol Suppl; 1997; 185():1-46. PubMed ID: 9249905
[TBL] [Abstract][Full Text] [Related]
16. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
17. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
[TBL] [Abstract][Full Text] [Related]
18. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
19. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
20. [Factors influencing the progression-free survival time of prostate cancer patients after endocrine therapy].
Guan YB; Zhang YF; Wen H; Zhou SQ; Dai YT
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):801-5. PubMed ID: 19947562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
